Can Lupus Affect the Eyes?

Patients with lupus know it can involve many organs and reasonably wonder about their eyes, especially when they notice dryness or blurred vision. Many are also started on hydroxychloroquine and told they need regular eye exams, which prompts them to ask what the drug does to the eyes and why the screening matters. Others are simply trying to understand whether a new visual symptom is a lupus flare or something separate.

Lupus is a systemic autoimmune disease that inflames tissues and small blood vessels throughout the body, and the eye is not exempt. On the surface, reduced tear production produces dry, gritty, irritated eyes. In the retina, lupus can damage the tiny vessels, producing cotton-wool spots, hemorrhages, and, in severe cases, blockage of retinal arteries or veins that can seriously reduce vision. The disease can also inflame the optic nerve or the blood vessels supplying the eye.

What makes the retinal effects important is their link to the disease as a whole. Lupus retinopathy is generally a sign that the lupus is active and more severe elsewhere, so an eye finding can be a window on the body. Separately, the medication that controls lupus, hydroxychloroquine, can slowly accumulate in the retina over years and, in a small number of patients, cause a specific type of retinal damage that is preventable if caught early through screening.

The eye conditions associated with lupus range from mild to sight-threatening. Keratoconjunctivitis sicca (dry eye), often part of secondary Sjogren's syndrome, is the most frequent. Lupus retinopathy, driven by immune-mediated damage and clotting in the small retinal vessels, is the most characteristic serious finding and correlates with disease activity; severe forms include occlusion of retinal arteries or veins. Lupus can also cause front-of-eye inflammation, optic neuritis or ischemic optic nerve damage, and, in patients who carry antiphospholipid antibodies, clotting events that block ocular vessels.

Medication effects deserve their own attention. Hydroxychloroquine is highly valuable in lupus but carries a small, dose- and duration-dependent risk of retinal toxicity, which is why guidelines call for a baseline exam and regular monitoring with sensitive tests. Long-term steroids, also used in lupus, can promote cataract and raise eye pressure. Because so many of these overlap, eye care in lupus is coordinated closely with the treating rheumatologist.

Dry eye in lupus is a comfort issue, but several eye symptoms in a lupus patient are more concerning and warrant prompt evaluation:

• New blurred vision, a blind spot, or distortion, which can reflect retinopathy or optic nerve involvement.
• Sudden vision loss, which can signal a blocked retinal vessel, a real risk in those with antiphospholipid antibodies.
• New changes in color vision or a dimming of vision, which can indicate optic nerve trouble or early medication effect.
• A red, painful eye with light sensitivity, suggesting inflammation inside the eye.

Sudden vision loss is an emergency; the others deserve prompt, not deferred, evaluation.

The doctor evaluates the surface for dry eye and performs a dilated retinal exam looking for the vascular changes of lupus retinopathy, checking vision, color vision, and pupils for optic nerve involvement. When retinopathy or vessel occlusion is suspected, retinal imaging such as OCT and fluorescein angiography documents the damage and guides treatment, and findings are shared with the rheumatologist because they reflect systemic activity. For patients on hydroxychloroquine, screening follows established practice: a baseline exam and periodic monitoring with sensitive tests including OCT of the macula and automated visual fields to detect early, still-reversible changes before vision is affected.

Dry eye is treated with artificial tears and ointment and, when needed, prescription anti-inflammatory drops and punctal plugs. Lupus retinopathy and optic nerve or vascular inflammation are treated primarily by controlling the underlying lupus, usually the rheumatologist intensifying systemic immunosuppression, sometimes with steroids or additional agents; patients with antiphospholipid-related clotting may need blood-thinning therapy. If hydroxychloroquine screening shows early retinal toxicity, the eye doctor and rheumatologist discuss stopping or adjusting the drug to prevent progression, since the damage does not reliably reverse once established. Any retinal or optic nerve complication is managed together with the systemic team.

• Do not skip your scheduled hydroxychloroquine screening exams; the early retinal changes are silent and best caught before symptoms.
• Do not stop or change your hydroxychloroquine on your own out of worry; discuss any concern with your rheumatologist and eye doctor.
• Do not dismiss new blurred vision, a blind spot, or color changes as a temporary flare without an exam.
• Do not ignore sudden vision loss, which can be a blocked retinal vessel and is an emergency.

Call to arrange dry-eye care and to set up hydroxychloroquine screening if you have lupus and take Plaquenil, and be seen promptly for new blurred vision, a blind spot, or color changes. Seek emergency care for sudden vision loss. May Eye Care Center, serving the Hanover, Pennsylvania area, can perform the screening tests, examine the retina and optic nerve, and coordinate with your rheumatologist.

Lupus can affect the eyes through dry eye, retinopathy, and optic nerve or vascular inflammation, and because the lupus medication hydroxychloroquine also requires retinal monitoring, regular eye care is an important part of managing the disease.